4D Pharma
74 Gartside Street
Manchester
M3 3EL
United Kingdom
Tel: 44-0-161-837-6205
Fax: 44-0-161-837-6201
Website: http://www.4dpharmaplc.com/
Email: info@4dpharmaplc.com
72 articles with 4D Pharma
-
4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq
6/28/2022
4D pharma plc announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC stating that in accordance with Listing Rules 5101, 5110, and IM-5101-1, Nasdaq Staff has determined that 4D pharma’s securities will be delisted from The Nasdaq Stock Market.
-
Update on Suspension of Trading
6/24/2022
4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, provides an update to the announcement released earlier regarding the Company’s request for an immediate suspension of trading in the Company’s ordinary shares on AIM which took effect from 12.30 p.m.
-
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 ASCO Annual Meeting
5/26/2022
4D pharma plc announced the presentation of a trial in progress poster from the Phase II clinical trial of MRx0518 in combination with BAVENCIO®, a PD-L1 blocking antibody, as a first-line maintenance therapy for patients with unresectable locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, at the 2022 ASCO Annual Meeting in Chicago, IL.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
4D pharma to Present at the H.C. Wainwright Global Investment Conference
5/19/2022
4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, announced that Duncan Peyton, Chief Executive Officer of 4D pharma, will present at the H.C. Wainwright Global Investment Conference.
-
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
5/17/2022
4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the presentation of a late-breaking poster on data from Part A of the Phase I/II trial of MRx-4DP0004 for the treatment of asthma.
-
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
3/31/2022
4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma
3/23/2022
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA ® (pembrolizumab) for the Treatment of Renal Cell Carcinoma.
-
The 4D pharma has shared positive interim results from its Phase I/II study of a combination therapeutic for the treatment of renal cell carcinoma (RCC).
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit
2/23/2022
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), today announced that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer of 4D pharma, will participate in a fireside chat at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 9:00 a.m. ET (2:00 p.m. GMT).
-
4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s Disease
2/22/2022
4D pharma plc today announces that the U.S. Food and Drug Administration (FDA) has cleared investigational new drug (IND) applications for two Live Biotherapeutics (LBPs), MRx0005 and MRx0029, for the treatment of Parkinson’s disease.
-
With IND approval, the therapeutics have become the first LBPs for Parkinson’s disease cleared by the FDA.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma
1/27/2022
4D pharma plc today announces additional clinical data from Part A of its Phase I/II trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.
-
4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004
1/20/2022
4D pharma plc today announced that it will host a virtual Key Opinion Leader (KOL) event to review previously disclosed positive topline results from Part A of its Phase I/II trial of MRx-4DP0004 for the treatment of asthma.
-
4D pharma to Present at the H.C. Wainwright BioConnect Conference
1/5/2022
4D pharma plc announced that Duncan Peyton, Chief Executive Officer of 4D pharma, and Alex Stevenson, Chief Scientific Officer of 4D pharma, will present at the H.C. Wainwright BioConnect Conference.
-
4D pharma appoints John Doyle as Chief Financial Officer
1/3/2022
4D pharma plc today announces the appointment of John Doyle as Chief Financial Officer (CFO).
-
4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma
12/13/2021
4D pharma plc today announces positive topline results from Part A of phase I/II clinical trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.